Aegis Capital Raises Aeon Biopharma PT to $7.2 Amid Strong Buy Rating

Aegis Capital Raises Aeon Biopharma PT to $7.2 Amid Strong Buy Rating

Aegis Capital has recently announced a significant increase in the price of Aeon Biopharma's PT, raising it to $7.2. This move comes amidst a strong buy rating, indicating a positive outlook from investors on the company's future prospects. The decision was likely influenced by recent advancements in the migraine treatment market, where Aeon Biopharma is a key player.

The migraine market is expected to experience substantial growth during the forecast period of 2024 to 2034, driven by increasing disease prevalence and awareness. Companies such as Eli Lilly and Company, Teva Pharmaceuticals, and Axsome Therapeutics are actively developing new pipeline products to revolutionize the market dynamics. In particular, Aeon Biopharma's ABP-450 is a promising therapeutic candidate that has shown potential in clinical trials.

In June 2025, Lundbeck's Vyepti (eptinezumab) successfully achieved both primary and secondary endpoints in its Phase IV RESOLUTION trial, demonstrating its effectiveness in reducing monthly migraine days. Similarly, AbbVie's atogepant, an oral CGRP receptor antagonist, met its primary endpoint in the Phase III TEMPLE study, showing fewer treatment discontinuations due to adverse events compared to topiramate.

These positive developments in the migraine treatment landscape have likely contributed to the strong buy rating and the subsequent increase in Aeon Biopharma's PT. Investors are optimistic about the company's ability to capitalize on the growing market and its promising pipeline of migraine treatments.